News

Public · Published

HC Wainwright & Co. reiterates Buy rating on Connect Biopharma Hldgs, $7 price target

HC Wainwright & Co. reiterated a Buy rating on Connect Biopharma stock with a $7.00 price target. That target implies 730.9% upside from the October 27 close of $0.84. The note cited an 81% reduction in treatment failure for rademikibart in the Seabreeze study.

Published:

Updated:

What happened

HC Wainwright & Co. reiterated a Buy rating on Connect Biopharma stock with a $7.00 price target. That target implies 730.9% upside from the October 27 close of $0.84. The note cited an 81% reduction in treatment failure for rademikibart in the Seabreeze study.

Confirmed

Global impact / market context

A $7 target far above the $0.84 close signals the analyst sees large potential value in rademikibart's COPD data. If that view holds, investors might reassess the shares, while the company could find it easier to raise money for future development.

Analyst inference

The reiterated Buy rating adds a bullish analyst voice on a low-priced biotech stock. The report ties the case to the Seabreeze trial result and rademikibart's approach to treating COPD flare-ups earlier, a claim investors may weigh against development and regulatory risk.

Analyst inference

What to watch

  1. Watch whether the 81% reduction in treatment failure from the Seabreeze study holds up in further data disclosures or later-stage testing, since that result underpins the analyst's bullish case. Confirmed
  2. Track how Connect Biopharma plans to fund the next steps for rademikibart, such as through partnerships or raising capital, because a small biotech company often needs outside cash. Proposed
  3. Watch for other analyst ratings or price target changes on Connect Biopharma, since wider agreement with HC Wainwright could shift investor positioning and support the stock's valuation. Analyst inference

Evidence

  • Original source link unavailable